We're very honoured to share that the @AmDiabetesAssn (ADA), @ADA_DiabetesPro is featuring PILA PHARMA AB in the "Thought Leadership Film Series", a part of ADA’s 81st Scientific Sessions program in June 2021, starting today. #Diabetes #research #T2D https://t.co/HlKJOTgkdb

#PRESS: PRECLINICAL STUDIES OF XEN-D0501 IN #OBESITY INITIATED https://t.co/ldN3VbF5Jo

💡 Aside from discussing the company, it was also pointed to obese pets 🐈 🐕 as a possible market for companies to enter with sufficiently scalable and efficient products! Thanks for the chat @joakimbaage 🤝 3/3 Link:

🚨 Last week we joined @Analyst_Group and @DirektStudios for a business update on @PILAPHARMA and our vastly #differentiated and simple small molecule oral #TRPV1 inhibitor! 2/3

💊 "#Oral solutions for #obesity will be dominating going forward, especially the solutions with the most #simple synthesis to allow for the most efficient #scalability" 🏭 1/3 #PILA

#PRESS: @PILAPHARMA ANNOUNCES PRE-CLINICAL OBESITY AND AMYLIN SPECIALIST PROFESSOR THOMAS LUTZ TO JOIN AS SCIENTIFIC ADVISER Link: https://t.co/RE4bHgmeSX

You can find links to the episodes here: Kort & Lång (shortened version) #Spotify: https://t.co/oqJoAzcWw7 #Apple: https://t.co/GWzF4SSmPM _______ #Noterat (full long version) #Spotify: https://t.co/rI2AGcdhFH #Apple:

We discuss: 💊 Oral medication for #obesity 📊 Trends within the #weightloss segment 📶 How we plan to be an #alternative 🚨 Where will #PILA be in 5 years? And many other interesting topics to existing and new investors! 💫

💥NEW #PODCAST ALERT💥 🎙 This week our CEO Gustav H. Gram features in the podcast "#Noterat" ("#Listed") together with Swedish #business media @dagensindustri!🌟 As part of their #KortochLång podcast, we feature in the episode from Monday Dec 1st and tomorrow Friday Dec 5th!💰

Thanks to the event partners #Aktieinfo, #ØkonomiskUgebrev & @aktiespararna ! #PILA If you missed the events, all the recordings can be found on our #youtube channel! Link to channel: https://t.co/2648FU8BFs 3/3

💊 Here existing and potential new investors got our insights to the #weightloss market, the trends we see in the sector, and the latest updates from @PILAPHARMA and our work to develop a new type of pill for #obesity & #diabetes! 2/3

🌲 EVENINGS OF #OBESITY CONVERSATIONS ✨ Last week we had the privilege to travel and engage with different forums of #investors! 🌟 🏆 4 days, 4 cities and 4 presentations was the result of our whirlwind trip when we visited #Aalborg, #Kolding, #Copenhagen & #Stockholm! 1/3

When the warm up was over (😉) they had the chance to hear our CEO Gustav H. Gram elaborate on the #obesity market and how we're progressing its uniquely #differentiated pill as a future treatment option in this highly attractive space 💊 Recording:

"A GREAT WARMUP" 🤔😉 Last week we participated at the annual #InvestorDagen! 🌟 More than 500 engaged private danish #investors turned up to listen to many prominent speakers such as the Chair of the Danish Centralbank, CEO of @NovoNordisk and the Danish Minister of FA💰

Learn more about the conference here: https://t.co/pZ1F4fVyCo

With @PILA_PHARMA's solution being an oral, potential first-in-class solution with a vastly differentiated mechanism (#TRPV1 inhibition), both CSO Dorte X. Gram & CEO Gustav H. Gram will be on-site to understand more and engage with the community 💊

Together with the preclinical proof-of-concept results achieved in #AbdominalAortaAneurysm (AAA) in December 2024 (unpublished), the team looks to build upon the #cardiovascular data in future studies 💓

In our PP-CT02 study, we observed a really strong and statistically highly significant reduction of a #heartfailure related biomarker called 'ANP'. This could indicate that our proprietary drug candidate has strong cardiovascular properties! 💡

In a future where 'whole-body' improvements are essential, addressing cardiovascular disease is of strong interest to @PILAPHARMA🔬

As the primary global convention for #cardiovascular science, we are really looking forward to attend for the first time to understand more from #clinicians and #pharma where the #cardiovascular science and developments are headed! 🩸

In extension of our participation at #ObesityWeek, @PILA_PHARMA is delighted to attend the @american_heart's #AHA25 convention next weekend in #NewOrleans 🇺🇸 #AHA25 #AHAScience #OW2025 #ObesityWeek